BioSig Subsidiary ViralClear Submits Application for Vicromax™ Through FDA’s Coronavirus Treatment Acceleration Program (CTAP) to Seek Acceleration of its Planned Clinical TrialsGlobeNewsWire • 04/21/20
Mayo Clinic preparing to Commence Phase II FDA clinical trial for the treatment of COVID-19 with Vicromax™GlobeNewsWire • 04/16/20
Positive Data Generated by Biosig Subsidiary ViralClear on Covid-19 Coronavirus Published in bioRxivGlobeNewsWire • 04/09/20
BioSig Technologies, Inc. (BSGM) CEO Ken Londoner on Development Updates Regarding Vicromax Conference Call (Transcript)Seeking Alpha • 04/07/20
BioSig to Host Telebriefing on Development Updates Regarding Vicromax(tm), a Novel Broad-Spectrum Anti-Viral Candidate That May Treat COVID-19GlobeNewsWire • 04/03/20
Jerome Zeldis, M.D., Ph.D, Appointed as Executive Chair of ViralClear Pharmaceuticals, Inc.GlobeNewsWire • 03/31/20
BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat COVID-19. Laboratory results demonstrate high level of activity against COVID-19 in cell cultureGlobeNewsWire • 03/25/20
BioSig Technologies Announces New Collaboration on Development of Artificial Intelligence Solutions in HealthcareGlobeNewsWire • 12/03/19
BioSig Technologies Welcomes the Creation of New Bioelectronic Medicine AllianceGlobeNewsWire • 11/18/19